ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
XT
XYone Therapeutics at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
XYone Therapeutics takes part in 3 sessions at ESMO 2026 in Madrid. Its work focuses on MUC1-targeting antibody–drug conjugates in stomach, prostate and bladder cancers. It examines the preclinical activity of these treatments, including an exatecan conjugate that targets MUC1-C.
| Organization | ESMO 2026 Attendance |
|---|---|
XT XYone Therapeutics Canton, MA | |
Oncology drug developer studying antibody–drug conjugates for cancer treatment. | Poster Fri Oct 23 13:00–15:00 MUC1-C Targeting ADC Exhibits Potent Anti-tumor Activity in KRAS-mutant Gastric Adenocarcinoma Gastrointestinal cancers Poster Fri Oct 23 15:15–16:00 Targeting MUC1 in advanced genitourinary malignancies: Expression landscape, molecular correlates, and preclinical activity of novel antibody-drug conjugates in prostate and bladder cancers Genitourinary cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 |
Find decision makers at XYone Therapeutics
Tell us what you sell and we’ll find the people at XYone Therapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction